论文部分内容阅读
目的 探讨p15/p16基因纯合性共丢失与原发性非小细胞癌(NSCLC)患者预后的相关性。方法 采用聚合酶链式反应(PCR)技术,先后检测140例NSCLC手术标本中p15/pl6双基因的共丢失。结果 肺腺癌组织中p15/pl6基因共丢失率明显高于肺鳞癌(P＜0.05),而双丢失组的患者生存率与患者的性别、年龄及TNM分期等因素无关(P＞0.05)。p15/pl6基因共丢失组的患者生存率明显低于未丢失组,两组之间呈著性差异(P＜0.01)。经统计学处理提示TNM分期对患者累计生存率的影响也具有明显差异(P＜0.05)。结论 据于p15/pl6基因共丢失率与肺癌患者生存期密切相关,因此检测pl5/pl6基因共丢失可作为NSCLC患者预后判断的指标。
Objective To investigate the association between the homozygous loss of p15/p16 gene and the prognosis of patients with primary non-small cell carcinoma (NSCLC). Methods The polymerase chain reaction (PCR) technique was used to detect the co-loss of p15/pl6 double genes in 140 surgical specimens of NSCLC. Results The rate of p15/pl6 gene loss in lung adenocarcinoma was significantly higher than that in lung squamous cell carcinoma (P<0.05). The survival rate of patients with double loss was not related to the gender, age, TNM stage and other factors (P>0.05). . The survival rate of the p15/pl6 gene loss group was significantly lower than that of the non-lost group. There was a significant difference between the two groups (P<0.01). Statistical analysis suggested that the effect of TNM staging on the cumulative survival rate of patients was also significantly different (P<0.05). Conclusions The co-losing rate of p15/pl6 gene is closely related to the survival period of lung cancer patients. Therefore, detecting the loss of pl5/pl6 gene can be used as an indicator of prognosis of NSCLC patients.